India, Oct. 27 -- Big drug companies no longer want to make everything themselves. Injectable pens, biologics and complex formulations need specialised plants, spotless quality records and years of regulatory work, so many hands that job to contract manufacturers. Winning that trust is slow, but once a product is approved and running, these relationships tend to last for years. That makes capacity and compliance the real currency of the business.

The Nifty 50 was trading at 22,714.65, down 0.18%. Meanwhile, Sensex also fell 0.26% to 73,411.18 on Tuesday. Meanwhile, Shares of OneSource Specialty Pharma were trading at Rs. 1,587.00, up 13.58 percent from previous close of Rs. 1,397.30. The stock opened at Rs. 1,402.70 and reached an intra...